Literature DB >> 9223324

Tat protein induces self-perpetuating permissivity for productive HIV-1 infection.

C J Li1, Y Ueda, B Shi, L Borodyansky, L Huang, Y Z Li, A B Pardee.   

Abstract

We report that human immunodeficiency virus type 1 (HIV-1) has evolved a self-perpetuating mechanism to actively generate cells permissive for productive and cytopathic infection. Only activated T cells can be productively infected, which leads to their rapid depletion (2 x 10(9)/day in an infected individual). Establishment of productive HIV-1 infection therefore requires continual activations from the large pool of quiescent T cells. Tat protein, which is secreted by infected cells, activated uninfected quiescent T cells in vitro and in vivo. These Tat-activated uninfected cells became highly permissive for productive HIV-1 infection. Activation of primary T cells by Tat protein involved integrin receptors and was associated with activation of mitogen-activated protein kinases, including ERK1 and JNK kinase. Accordingly, these primary T cells progressed from G0 to the late G1 phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223324      PMCID: PMC21566          DOI: 10.1073/pnas.94.15.8116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  T-cell dynamics of immunodeficiency.

Authors:  M Roederer
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

Review 2.  Viral latency in HIV disease.

Authors:  J M McCune
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

3.  Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma.

Authors:  B Ensoli; R Gendelman; P Markham; V Fiorelli; S Colombini; M Raffeld; A Cafaro; H K Chang; J N Brady; R C Gallo
Journal:  Nature       Date:  1994-10-20       Impact factor: 49.962

4.  Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo.

Authors:  M C Re; G Furlini; M Vignoli; E Ramazzotti; G Roderigo; V De Rosa; G Zauli; S Lolli; S Capitani; M La Placa
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-12-01

5.  Expression of Fas/APO-1 during the progression of astrocytomas.

Authors:  O Tachibana; H Nakazawa; J Lampe; K Watanabe; P Kleihues; H Ohgaki
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

6.  Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.

Authors:  M O Westendorp; R Frank; C Ochsenbauer; K Stricker; J Dhein; H Walczak; K M Debatin; P H Krammer
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

7.  Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection.

Authors:  J Borvak; C S Chou; K Bell; G Van Dyke; H Zola; O Ramilo; E S Vitetta
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

8.  Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation.

Authors:  S Tang; B Patterson; J A Levy
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals.

Authors:  P D Katsikis; E S Wunderlich; C A Smith; L A Herzenberg; L A Herzenberg
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more
  32 in total

1.  Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.

Authors:  S S Cohen; C Li; L Ding; Y Cao; A B Pardee; E M Shevach; D I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.

Authors:  R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

3.  Activation of transcription of the human cytomegalovirus early UL4 promoter by the Ets transcription factor binding element.

Authors:  J Chen; M F Stinski
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  HIV Tat controls RNA Polymerase II and the epigenetic landscape to transcriptionally reprogram target immune cells.

Authors:  Jonathan E Reeder; Youn-Tae Kwak; Ryan P McNamara; Christian V Forst; Iván D'Orso
Journal:  Elife       Date:  2015-10-21       Impact factor: 8.140

5.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.

Authors:  Ruth H Florese; Roger W Wiseman; David Venzon; Julie A Karl; Thorsten Demberg; Kay Larsen; Leon Flanary; V S Kalyanaraman; Ranajit Pal; Fausto Titti; L Jean Patterson; Megan J Heath; David H O'Connor; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2008-04-30       Impact factor: 3.641

7.  HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia.

Authors:  Gideon Goldstein; Eve Damiano; Mardik Donikyan; Malika Pasha; Erik Beckwith; John Chicca
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

8.  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Authors:  Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard
Journal:  J Med Chem       Date:  2013-10-03       Impact factor: 7.446

9.  Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Authors:  Barbara Ensoli; Stefania Bellino; Antonella Tripiciano; Olimpia Longo; Vittorio Francavilla; Simone Marcotullio; Aurelio Cafaro; Orietta Picconi; Giovanni Paniccia; Arianna Scoglio; Angela Arancio; Cristina Ariola; Maria J Ruiz Alvarez; Massimo Campagna; Donato Scaramuzzi; Cristina Iori; Roberto Esposito; Cristina Mussini; Florio Ghinelli; Laura Sighinolfi; Guido Palamara; Alessandra Latini; Gioacchino Angarano; Nicoletta Ladisa; Fabrizio Soscia; Vito S Mercurio; Adriano Lazzarin; Giuseppe Tambussi; Raffaele Visintini; Francesco Mazzotta; Massimo Di Pietro; Massimo Galli; Stefano Rusconi; Giampiero Carosi; Carlo Torti; Giovanni Di Perri; Stefano Bonora; Fabrizio Ensoli; Enrico Garaci
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

10.  Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells.

Authors:  Xiangrong Gao; Haoran Wang; Takeshi Sairenji
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.